Image Courtesy: News-Medical
Scientists investigating a potential treatment for Alzheimer’s disease have made an unexpected discovery: a peptide they originally engineered in the laboratory also appears to occur naturally in the human body. Researchers found that levels of the molecule, known as HAEE, were nearly twice as low in people diagnosed with Alzheimer’s compared with healthy volunteers, raising questions about its potential role in the disease.
The findings, published in PNAS Nexus on October 20, could open new avenues for investigating Alzheimer’s biomarkers and treatments. However, researchers say further studies are needed to confirm the molecule’s identity, understand how the body produces it, and determine whether supplementing it could slow disease progression.
The discovery emerged from research led by scientists at Russia’s Engelhardt Institute of Molecular Biology. The team initially developed HAEE to interfere with the accumulation of amyloid-beta, a protein associated with Alzheimer’s disease. In earlier research published in 2015, the researchers found that the synthetic peptide could inhibit amyloid-beta aggregation in mice.
Alzheimer’s disease involves several biological processes, including the accumulation of amyloid-beta plaques and abnormal tau protein deposits in the brain. These changes are associated with damage to nerve cells and declining memory and cognitive function, although the precise mechanisms driving the disease remain under investigation.
In 2021, the researchers developed a method to measure HAEE concentrations in biological samples as they prepared for potential clinical trials. While analyzing blood plasma from 150 people without diagnosed cognitive impairment, they discovered that the peptide appeared to be naturally present in human blood, according to Newsweek.
Lead researcher Sergey Kozin said the finding fundamentally changed his research priorities. He had previously considered HAEE primarily a potential treatment but now believes its natural presence could indicate a broader role in nervous system regulation.
The team subsequently compared samples from 200 people diagnosed with Alzheimer’s and 150 participants without cognitive impairment. The results showed that HAEE levels were approximately half as high in the Alzheimer’s group.
Kozin suggested that restoring the peptide through injections or nasal administration might eventually help slow disease progression. However, this remains a hypothesis, not a demonstrated treatment effect. The study did not establish that low HAEE levels cause Alzheimer’s or that administering the peptide benefits patients.
Independent experts have also urged caution. Ottavio Arancio, a professor at Columbia University, called the findings interesting but emphasized the need to confirm the molecule’s identity and investigate possible differences in how blood samples were collected and handled.
If independently validated, the discovery could provide a new direction for Alzheimer’s research. For now, further laboratory studies and clinical trials will be necessary to determine whether HAEE can become a reliable biomarker or an effective treatment.
